Rejected at 8:28 p.m. Oct, 31, 2023 ] by dollajas
Author: dopamine
Related Note: 1495740310438
Rationale for change

Contents of the card are completely irrelevant to the tagged B&B video

Rejection reason

resolved manually

Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
Changed Tags
#AK_Step1_v12::#B&B::08_Endocrinology::04_Repro::01_Repro_Hormones #AK_Step1_v12::#OME_banner::Clinical::07_Endocrinology
#AK_Step2_v12::#B&B::09_MSK::01_General::04_Systemic_Lupus_Erythematosus::Extra #AK_Step2_v12::#SketchyIM::03_Pulmonology::09_Retired_Lessons::03_Restrictive_Pulmonary_Diseases::02_Granulomatous_ILDs_SOAP_[OLD_VERSION] #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #PANCE::EOR::IM #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::^Other::^EXPN #PANCE::RENAL::Nephrotic_Nephritic #AK_Step2_v12::#SketchyIM::07_Rheumatology::08_Vasculitis_&_Vascular_Disorders::01_Small_Vessel_Vasculitides:_GPA_EGPA_Thromboangiitis_Obliterans #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::02_DNA_&_Cellular_Division::01_Alkylating_Agents::zanki_extra #AK_Step2_v12::#SketchyIM::04_Nephrology_&_Urology::01_Nephrology::02_Glomerulonephritis_SOAP #AK_Step1_v12::#Pixorize::01_Biochemistry::13_Vasculitides::08_Microscopic_Polyangiitis #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#AMBOSS::Mx0MCR #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::08_Cyclophosphamide/Ifosfamide #AK_Step1_v12::#Pixorize::01_Biochemistry::13_Vasculitides::06_Granulomatosis_with_Polyangiitis #AK_Step2_v12::#AMBOSS::mx0VCR #AK_Step2_v12::#B&B::09_MSK::01_General::06_Vasculitis::Extra #AK_Step1_v12::#OME::Clinical::Intern_Bootcamp #AK_Step1_v12::#B&B::13_Immunology::03_Pharm::02_Immunosuppressive_Drugs #AK_Other::!AK_UpdateTags::AnKing_Image::AhmedA::Polyarteritis_Nodosa #AK_Step1_v12::#Bootcamp::Musculoskeletal::03_Rheumatologic_Disease::02_Systemic_Lupus_Erythematosus #AK_Step2_v12::#SketchyIM::07_Rheumatology::08_Vasculitis_&_Vascular_Disorders::02_Medium_Vessel_Vasculitides:_Polyarteritis_Nodosum #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::13_Alkylating_agents::*Cyclophosphamide #AK_Step1_v12::#B&B::13_Immunology::04_Autoimmune_Disorders::05_Vasculitis::Extra #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::11_Busulfan_Cyclophosphamide_Ifosfamide_Nitorsureas #AK_Other::!AK_UpdateTags::AnKing_Image::!Subjects::Orthopedics_&_Rheumatology::Polyarteritis_Nodosa #AK_Step2_v12::#SketchyIM::07_Rheumatology::07_Systemic_Diseases::02_Systemic_Lupus_Erythematosus_SOAP